Novo Nordisk's Ozempic, originally a diabetes treatment, has received FDA approval to reduce risks associated with chronic kidney disease. Clinical trials showed a 24% reduction in disease worsening and a 5% decrease in heart disease death risk for adults with both type 2 diabetes and chronic kidney disease.
Diabetes is the leading cause of kidney failure, which is one of the leading causes of death in the US and worldwideOzempic has now also been approved by the FDA to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.
Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of kidney failure, which is one of the leading causes of death in the US and worldwide; about a third of adults with diabetes also have chronic kidney disease, according to the US Centers for Disease Control and Prevention
Novo Nordisk is conducting a different study to understand how and why semgalutide seems to reduce the progression of kidney disease, said Stephen Gough, global chief medical officer and senior vice president at Novo Nordisk. But even though scientists don't fully understand the mechanisms behind them, the positive effects are strong: The clinical study was stopped early after reaching positive endpoints sooner than expected, and no new safety risks were identified in this trial, he said.
CHRONIC KIDNEY DISEASE DIABETES OZEMPIC NOVO NORDSIK FDA APPROVAL
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug’s Latest ApprovalRegulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and strokes.
Read more »
Ozempic Approved to Reduce Risks of Chronic Kidney DiseaseOzempic, initially approved for Type 2 diabetes, has received FDA approval to mitigate risks associated with chronic kidney disease. A Phase 3 trial demonstrated a 24% reduction in kidney disease progression and a 5% decrease in heart-related death risk for patients with both diabetes and chronic kidney disease.
Read more »
FDA Approves Ozempic for Chronic Kidney Disease and Diabetes, Expanding Treatment OptionsThe Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, marking a significant advancement in the treatment of these interconnected conditions. This approval could transform how doctors manage chronic kidney disease, a major health concern in the United States.
Read more »
FDA Approves Ozempic for Chronic Kidney Disease and DiabetesIn a landmark decision, the FDA has approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes. This approval expands the use of the popular injection and could revolutionize the treatment of these interconnected conditions.
Read more »
Microdosing Ozempic for Weight Loss: A Risky Trend Gaining PopularityA new trend sees people microdosing Ozempic, a diabetes medication, for weight loss. While both Ozempic and Wegovy are approved for their respective purposes, microdosing Ozempic, using smaller doses than prescribed, is not approved by the FDA. Experts warn against this practice due to the lack of established guidelines and potential risks.
Read more »
First FDA-Approved Treatment for Dry AMD Shows Promising ResultsLumiThera's Valeda Light Delivery System significantly reduces vision loss and geographic atrophy in dry AMD patients.
Read more »